BioSpace News Archive

Business

NovaBay Pharmaceuticals Announces Changes to Its Board of Directors

NovaBay ® Pharmaceuticals, Inc . announces the appointments of Audrey Kunin, M.D. and Julie Garlikov to the NovaBay Board of Directors.

January 28, 2022
·
6 min read
Pharm Country

Lava Therapeutics Announces Participation in the SVB Leerink 11th Annual Global Healthcare Conference 2022

LAVA Therapeutics N.V., a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, announced that Stephen Hurly, president and chief executive officer, will present the latest company overview at the SVB Leerink 11th Annual Global Healthcare Conference 2022.

January 28, 2022
·
3 min read
Genetown

AVROBIO to Present at Cowen’s 2nd Annual Genetic Medicines Summit

AVROBIO, Inc. announced Azadeh Golipour, Ph.D., chief technology officer at AVROBIO, will present virtually at Cowen’s 2nd Annual Genetic Medicines Summit at 2:00 p.m. ET on Thursday, Feb. 3, 2022.

January 28, 2022
·
5 min read
Much Awaited, Much Needed: TRANSFORM II Randomized Controlled Trial, by Fondazione RIC, gets rolling

FONDAZIONE Ricerca e Innovazione Cardiovascolare, Milano , focused on cardiovascular research, reports the first patient enrolment of the TRANSFORM II.

January 28, 2022
·
4 min read
Business

Monrol Signing Agreement to License its GMP Grade Lu-177 n.c.a Production Technology to Curium

Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) has today announced it has signed an agreement with Curium Netherlands B.V (Curium) to license its GMP grade medical radioisotope, no-carrier-added 177 Lu (n.c.a. 177 Lu) cutting-edge production technology LuMagic®.

January 28, 2022
·
4 min read
Business

I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics Drugs

I-Mab announced the signing of a partnership agreement with the Hangzhou Qiantang New Area in China to manufacture its innovative drugs locally and accelerate its transition to commercialization.

January 28, 2022
·
6 min read
Biotech Beach

Sorrento Announces Its Oral SARS-CoV-2 Main Protease (Mpro) Inhibitor, STI-1558, Strongly Neutralizes Omicron

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced its late-stage preclinical Mpro inhibitor, STI-1558, effectively inhibits Omicron virus entry and replication in cell-based assays.

January 28, 2022
·
6 min read
CTB001, Bioheng auto CAR - T Product, received Orphan Drug Designation (ODD) from the U.S. FDA

Recently, Nanjing Bioheng Biotech Co., Ltd. ( hereinafter referred to as Bioheng) announced that its anti-claudin 18.2 autologous CAR-T cell therapy product CTB001 received Orphan Drug Designation (ODD) from the Food and Drug Administration (FDA) for the treatment of gastric cancer.

January 28, 2022
·
3 min read
Inspira Technologies Has Listed an FDA Class I 510(k) Exempt component of the ART system

Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the “Company” or “Inspira Technologies”), a groundbreaking respiratory support technology company, announced today that has listed a component of its ART and ECLS systems on the U.S. Food and Drug Administration Class I 510(k) exempt list.

January 28, 2022
·
2 min read
Biotech Bay

World-Renowned Heart Failure Physicians To Feature Innovative Heart Failure Therapies at Technology and Heart Failure Therapeutics, February 1-2, 2022

Innovative therapeutic approaches for the left ventricle may slow progression or reverse congestive heart failure.

January 28, 2022
·
3 min read